All In Biotech

Drug Trial Radar · NCT04538625

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 287 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

287

Actual

Start

Oct 7, 2020

Primary completion

Aug 7, 2023

Study completion Oct 30, 2023

Sponsor

Lead sponsor
Napo Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Sep 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 24-week, (two 12-week stages), randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors treated with targeted cancer therapy-containing treatment regimens. Diarrhea grading will be done according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Patients will be randomized 1:1 to placebo or crofelemer and will be stratified by the type of targeted cancer therapy and the tumor type. Placebo and/or crofelemer will be dispensed at Visit 1/Day 1 with the concurrent start of the targeted cancer therapy regimen. The initial Stage I double-blind placebo-controlled primary treatment phase will occur over a 12-week period to accommodate approximately 3 cycle chemotherapy cancer treatment dosing-cycles. The Primary and Secondary Endpoints will be analyzed after the last patient last visit (LPLV) of Stage I. After completing the Stage I double-blind, placebo-controlled primary treatment phase, the subjects will have the option to remain on their assigned treatment arm and reconsented to enter into the Stage II extension phase. Reconsent will be required to enter into Stage II. For subjects who do not reconsent, visit 5 will be the last study visit.

Conditions

  • Cancer Therapy-Related Diarrhea
  • Chemotherapy-related Diarrhea
  • Adult Solid Tumor
  • Prophylaxis of Diarrhea
  • Symptomatic Relief of Diarrhea
  • Targeted Therapy-related Diarrhea

Interventions

  • Crofelemer 125 MG [Mytesi]Drug

    Randomized, Double-blind, Placebo-controlled, two arm trial

  • PlaceboDrug

    Matching placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Number of Loose/watery StoolsTime frame: For the entire 12-week double-blind placebo-controlled treatment period (The Stage 1 Primary Treatment Phase).

Locations

52 sites in 5 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates PC - HAL

    Prescott, Arizona

  • Pacific Cancer Medical Center Inc

    Anaheim, California

  • The Oncology Institute of Hope and Innovation

    Corona, California

  • The Oncology Institute of Hope and Innovation

    Glendale, California

  • PIH Health Whittier Hospital

    Whittier, California

  • SCL Health Research Institute

    Lafayette, Colorado

  • GenesisCare USA

    Aventura, Florida

  • Cancer Care Centers of Brevard, Inc.

    Palm Bay, Florida

  • BRCR Global

    Plantation, Florida

  • Advanced Research Institute

    St. Petersburg, Florida

  • American Oncology Partners of Maryland

    Bethesda, Maryland

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • North Shore Hematology Oncology Associates dba New York Cancer and Blood Specialists

    Port Jefferson Station, New York

  • Jacobi Medical Center

    The Bronx, New York

  • Gabrail Cancer Research

    Canton, Ohio

  • Oregon Health & Science University (OHSU) Knight Cancer Institute

    Portland, Oregon

  • The West Clinic Research

    Germantown, Tennessee

  • Texas Oncology - Denison

    Denison, Texas

  • Texas Oncology, P.A. - Flower Mound

    Flower Mound, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - New Braunfels

    New Braunfels, Texas

  • Texas Oncology - Plano East

    Plano, Texas

  • Texas Oncology - Gulf Coast

    Webster, Texas

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • Shenandoah Oncology Associates

    Winchester, Virginia

  • MultiCare Institute for Research and Innovation

    Tacoma, Washington

  • Fleischer Medical Center

    Buenos Aires, Argentina

  • Medical Center Austral

    Buenos Aires, Argentina

  • Buenos Aires British Hospital

    Buenos Aires, Argentina

  • Cordoba Oncology Institute (IONC)

    Córdoba, Argentina

  • Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)

    Paraná, Argentina

  • CEDIT Diagnostic and Treatment Center

    Salta, Argentina

  • 9 of July Sanatorium

    San Miguel de Tucumán, Argentina

  • Isis Specialized Clinic

    Santa Fe, Argentina

  • LLC "Todua Clinic"

    Tbilisi, Georgia

  • Archangel St. Michael Multiprofile Clinical Hospital LTD

    Tbilisi, Georgia

  • JSC K. Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC

    Tbilisi, Georgia

  • LTD Caucasus Medical Centre

    Tbilisi, Georgia

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.